Drug Information

Drug General Information
Drug ID
D04FYU
Former ID
DIB005005
Drug Name
DMP-444
Indication Coronary artery disease [ICD9: 410-414, 429.2; ICD10:I20-I25] Phase 3 [531571]
Company
Bristol-Myers Squibb Pharma Co
Target and Pathway
Target(s) Glycoprotein IIb/IIIa receptor Target Info Modulator [526689]
Reactome Platelet degranulation
Elastic fibre formation
PECAM1 interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Syndecan interactions
ECM proteoglycans
Integrin alphaIIb beta3 signaling
GRB2:SOS provides linkage to MAPK signaling for Integrins
p130Cas linkage to MAPK signaling for integrins
VEGFA-VEGFR2 Pathway
MAP2K and MAPK activation
WikiPathways Focal Adhesion
Hematopoietic Stem Cell Differentiation
Human Complement System
Extracellular matrix organization
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Integrin alphaIIb beta3 signaling
References
Ref 531571Evaluation of 99mTc-labeled cyclic RGD peptide with a PEG4 linker for thrombosis imaging: comparison with DMP444. Bioconjug Chem. 2011 Aug 17;22(8):1715-22.
Ref 526689Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.